High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers

2015 ◽  
Vol 467 (6) ◽  
pp. 701-709 ◽  
Author(s):  
Hee Jin Lee ◽  
Joo Young Kim ◽  
In Hye Song ◽  
In Ah Park ◽  
Jong Han Yu ◽  
...  
Keyword(s):  
High Mobility ◽  
Tumor Infiltrating Lymphocytes ◽  
High Mobility Group ◽  
Breast Cancers ◽  
Her2 Positive ◽  
Infiltrating Lymphocytes

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

2015 ◽  
Vol 33 (9) ◽  
pp. 983-991 ◽  
Author(s):  
Carsten Denkert ◽  
Gunter von Minckwitz ◽  
Jan C. Brase ◽  
Bruno V. Sinn ◽  
Stephan Gade ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Tumor Infiltrating Lymphocytes ◽  
Breast Cancers ◽  
Her2 Positive ◽  
Epidermal Growth ◽  
Infiltrating Lymphocytes ◽  
Mrna Markers

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. Patients and Methods GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, CCL5, CD8A, CD80, CXCL13, IGKC, CD21) as well as immunosuppressive factors (IDO1, PD-1, PD-L1, CTLA4, FOXP3) was measured in 481 tumors. Results Increased levels of stromal TILs predicted pCR in univariable (P < .001) and multivariable analyses (P < .001). pCR rate was 59.9% in LPBC and 33.8% for non-LPBC (P < .001). pCR rates ≥ 75% were observed in patients with LPBC tumors treated with PMCb, with a significant test for interaction with therapy in the complete (P = .002) and HER2-positive (P = .006), but not the TNBC, cohorts. Hierarchic clustering of mRNA markers revealed three immune subtypes with different pCR rates (P < .001). All 12 immune mRNA markers were predictive for increased pCR. The highest odds ratios (ORs) were observed for PD-L1 (OR, 1.57; 95% CI, 1.34 to 1.86; P < .001) and CCL5 (OR, 1.41; 95% CI, 1.23 to 1.62; P < .001). Conclusion Immunologic factors were highly significant predictors of therapy response in the GeparSixto trial, particularly in patients treated with Cb. After further standardization, they could be included in histopathologic assessment of BC.

Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer

2016 ◽  
Vol 66 (4) ◽  
pp. 202-209 ◽  
Author(s):  
Hee Jin Lee ◽  
Ahrong Kim ◽  
In Hye Song ◽  
In Ah Park ◽  
Jong Han Yu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Mobility ◽  
Tumor Infiltrating Lymphocytes ◽  
High Mobility Group ◽  
Cytoplasmic Expression ◽  
Infiltrating Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document